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Abstract
Purpose—Results from our oral cavity chemoprevention trial demonstrated appreciable
interpatient variations regarding chemopreventive efficacy of a freeze dried black raspberry (FBR)
gel. We speculated these data reflected individual patient-related differences in absorption, target
tissue uptake and local compound metabolism of key FBR compounds (anthocyanins).
Accordingly, this study assessed the distribution of anthocyanins from the 10% (w/w) FBR gel in
saliva, oral tissues and plasma.
Methods—Human subject participation entailed collection of: (1) saliva, tissue and plasma (5
min following gel application, keratinized tissues), (2) saliva and plasma (5 min after sublingual
gel application), (3) saliva and plasma at 1, 2, and 4 h post gel application (keratinized tissues),
and (4) saliva (cyanidin 3-rutinoside incubations). Levels of FBR anthocyanins in the respective
samples were analyzed by LC/MS/MS.
Results—Our data show: significantly higher anthocyanin levels in saliva and oral tissues
relative to matched plasma samples, marked donor-specific variations in anthocyanin uptake,
sustainability of anthocyanins at the target site, pH affects anthocyanin penetration and intraoral
anthocyanin decomposition and/or metabolism.
Conclusions—No previous oral cavity chemoprevention trials evaluated compound distribution
at the treatment site. Our data, which demonstrate a local delivery-derived pharmacologic
advantage, provide insights which could advance oral cavity chemoprevention strategies.
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INTRODUCTION
Oral squamous cell carcinoma (oral SCC), which arises from dysplastic surface epithelium
lining the mouth, comprises 90% of oral cavity cancers (1). Analogous to other carcinomas,
oral SCCs do not arise de novo, but develop through a series of progressive perturbations in
the overlying epithelium (1). Management for oral SCC entails wide surgical excision, and
may also include intra and/or postoperative radiation therapy (2,3). Despite these aggressive
treatments, the overall survival rates for oral SCCs remain among the lowest of major
cancers (4). Clearly, prevention of oral SCC development by inhibiting malignant
transformation of dysplastic oral lesions could be beneficial. The current standard of care for
precancerous oral lesions entails clinical monitoring in conjunction with either surgical
excision or laser ablation for more histologically advanced (moderate dysplasia or higher)
lesions (1). Notably, approximately one third of oral dysplastic lesions recur despite
complete excision with microscopically confirmed clear margins (5,6). Further, while not all
oral epithelial dysplasias progress to oral SCC, we are currently unable to determine which
lesions will undergo malignant transformation (6).
Chemoprevention, which is defined as the use of naturally or synthetically derived
compounds to promote regression or prevent progression of premalignant lesions, represents
a promising oral cancer prevention strategy (7). Because it is visibly accessible, the mouth
has two significant aspects that facilitate chemoprevention. First, clinicians can directly
monitor the response of lesional tissues during treatment. Secondly, topical approaches are
feasible because patients can see their lesions—a factor that facilitates agent application to
the target site.
To date, the majority of oral cancer chemoprevention trials have employed systemic
administration of the study compounds (8-12). Due to the established differentiation-
inducing effects of retinoids, vitamin A and retinoic acid derivatives represent some of the
most intensely evaluated oral cavity chemopreventive agents (8-12). These results, however,
have been disappointing (8-12). Plausible explanations for the suboptimal results included
the relative recalcitrance of the oral cavity lesions to treatment and the apparent inability to
obtain therapeutically effective local levels without inducing systemic toxicities (8-12).
Previous local delivery attempts for oral cavity chemoprevention have also encountered
difficulties (13,14). The ONYX-15 trial, which evaluated a mouthwash that targeted p53
defective cells, initially showed efficacy (13). This study, however, was discontinued after a
trial participant developed circulating antibodies against the adenoviral vector used to target
the p53 defective oral epithelial cells (13). Results from the mouthwash trial that evaluated
the cyclooxygenase inhibitor ketorolac showed that while both the placebo and active rinses
were well-tolerated, the active formulation provided no significant reductions in the extent
of leukoplakia (14).
Our labs have shown that freeze dried black raspberries (FBR) convey chemopreventive
effects at both the in vitro and in vivo levels (15-19). Recently, we developed a prototype
mucoadhesive gel that contained FBR for evaluation as a prospective oral cavity
chemopreventive agent (20). The FBR content of the prototype gel was increased from 5%
to 10% w/w and the pH was reduced to 3.5 to preserve the anthocyanins in the more stable
flavylium cation form for use in our recently completed Phase I/II chemoprevention trial.
Treatment entailed topical gel application to oral dysplastic lesions (0.5 g four-times per day
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for 6 weeks) (21,22). Trial results show that gel application significantly reduced loss of
heterozygosity indices at loci associated with tumor suppressor genes, suppressed genes
associated with RNA processing, growth factor recycling and inhibition of apoptosis and
significantly reduced cyclooxygenase two levels in treated lesional epithelium (21,22).
Our clinical trial data also showed extensive interpatient differences with regard to agent
responsiveness (21,22). We speculate that these variations reflect differences in local
pharmacokinetics with factors such as absorption, penetration, and potentially FBR
metabolism all impacting therapeutic outcomes. The purposes of the current study were to
determine: (1) whether topical FBR gel provides a pharamacologic advantage i.e. deliver
higher levels of therapeutic compounds at the local treatment site relative to systemic levels,
(2) distribution and possible sustainability of FBR anthocyanins following topical intraoral
FBR gel application. Our findings show compound compartmentalization at the targeted site
with highest levels obtained in saliva, intermediate levels in tissues, and non-detectable
levels in plasma, considerable interdonor heterogeneity with regard to saliva and tissue
levels achieved, and donor-related variations in gel absorptive capacity. Similarly, the time
course and sublingual application site studies show appreciable interdonor variations with
regard to therapeutic compound i.e. FBR anthocyanin retention in saliva and confirm
negligible systemic uptake from intraoral tissue locations.
MATERIALS AND METHODS
Berry Gel Manufacturing
The bioadhesive gels used in these studies were prepared using current Good Manufacturing
Practices (cGMP) at the cGMP facility within the Center for Pharmaceutical Science and
Technology at the University of Kentucky, Lexington, KY. The quality control measures
and details of the gel composition and method of manufacture have been described
previously (20). Briefly, the gel composition used for the clinical trial consisted of (percent
w/w): Noveon AA1 (NF) (Noveon, Inc., Cleveland, OH) 1.35%, Carbopol 971P (NF) (BF
Goodrich Specialty Chemicals, Cleveland, OH) 1.575%, glycerin (USP) 1.0%, edentate
disodium (USP) 0.1%, 2-phenoxyethanol (BP) 1.0%, benzyl alcohol (USP) 1.0%, FBR 10%,
and purified water to reach 100% (20). For the clinical trial, and this current study, the
prototype gel’s FBR concentration was increased to 10% (w/w) and the pH was fixed at pH
3.5 to stabilize the more biologically active flavylium cation of the anthocyanin molecules
for the clinical trial (21,22).
Human Subjects’ Participation
Thirty total human subjects participated in this study which was approved by The Ohio State
University Institutional Review Board. Twenty three adults, who were undergoing elective
oral surgical procedures, were consented to participate in the tissue compartmentalization
studies. Three of these consented donors (001, 003 and 022) did not complete study
participation due to difficulty in obtaining adequate saliva volumes for analyses. Exclusion
criteria for this component of the study included partially erupted mandibular third molars,
or any sign of ulceration or inflammation in the tissue overlying these teeth. The retromolar
pad tissue was dried, then 0.5 g of gel was massaged at the site for 30 s to facilitate uptake.
Five minutes after gel application, saliva (collected for 1 min) and peripheral blood samples
were obtained. The gel treated tissue overlying the third molar was then removed for
surgical access. A second, single time point study entailed sublingual application of 0.5 g gel
in five donors, followed by collection of saliva and plasma 5 min following gel application.
A third aspect of the study consisted of time course analyses in which plasma and saliva
samples were obtained from five donors at baseline (plasma only), 1, 2 h (saliva only) and 1
and 4 h (plasma) following application of 0.5 g FBR gel to the retromolar pad. Donors in the
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time course studies had free access to liquids following gel application. The demographics
of the human subject participants are presented in Tables I, II, III, and IV.
All subjects completed a food history sheet which addressed consumption and quantity of
anthocyanin-rich foods such as berries, cherries, purple grapes and red wine, for the 24 h
that preceded their study participation. While some of the study participants reported a
modest recent consumption of some anthocyanin-rich foods, baseline samples from these
donors revealed nondetectable saliva or plasma levels prior to gel application.
Handling of the Saliva, Plasma and Tissue Samples
Volumes of the saliva samples were recorded, followed by addition of formic acid (5% final
concentration). Peripheral blood samples were centrifuged, plasma volumes recorded,
followed by addition of formic acid. Following acidification, saliva and plasma samples
were stored at −80°C until LC/MS/MS analyses. The human tissue samples comprised of
surface epithelium and associated connective tissue were immediately placed in formic acid
and stored at −80°C until preparation for the LC-MS/MS analyses. Prior to analyses, tissues
were washed with phosphate buffered saline (PBS), homogenized on ice, and aliquots
removed for protein determination via the Lowry assay (23). To facilitate tissue preparation
to constituent components, homogenized samples were subsequently treated with trypsin
2.5% and collagenase I 2.0% (Worthington Biochemical Corporation, Lakewood, New
Jersey) for 1.5 h at 37°C, followed by acidification with formic acid. To assess the effects of
this tissue processing protocol on anthocyanin stability, additional studies were conducted
which entailed addition of known amounts of cyanidin 3-rutinoside (500 ng/ml and 32 μg/
ml) to control oral mucosal tissues prior to preparation. Saliva levels were reported as total
anthocyanins, while tissue and plasma were reported as nanograms per milligram protein
and micrograms per milliliter, respectively.
LC/MS/MS Analyses to Determine Levels of FBR Anthocyanins in the Human Samples
Anthocyanins were selected as the targeted compounds for the PK analyses for two reasons.
First, anthocyanins are the predominant phenolic compounds in FBR (24). Secondly, our
labs have shown that anthocyanin-enriched FBR extracts possess high chemopreventive
impact (25). The four FBR anthocyanins (highest to lowest levels, respectively) are:
cyanidin 3-rutinoside, cyanidin 3-xylosylrutinoside, cyanidin 3-sambubioside, and cyanidin
3-glucoside. Cyanidin 3-glucoside, malvidin 3-glucoside, cyanidin 3-sambubioside, and
cyanidin 3-rutinoside standards were obtained from Polyphenols Laboratory AS (Hanaveien
4-6, N-4327, Sandens, Norway). Malvidin 3-glucoside was selected as the internal standard
as described previously by Stoner et al. (26). Due to the lack of a standard for cyanidin 3-
xylosylrutinoside, the calibration curve of cyanidin 3-rutinoside was used with an ion
transition channel at m/z 727.00>287.00 (E=35%). The standards and the human samples
were analyzed using a TSQ quantum triple mass spectrometer (ThermoFinnigan, San Jose,
CA) under an electrospray ionization (ESI) positive mode (standard curves ranged from 1 to
1,000 ng/ml, R2>0.99). The mean accuracies between and within runs were >98%, with an
average coefficient of variance around 8%. The minimum detectable levels for the 4 FBR
anthocyanins were 0.2 ng/ml in 0.4 ng/ml human plasma, 1 ng/ml in 0.2 ml diluted saliva (at
least a 20 fold dilution) and 1.0 ng/ml for tissue homogenates. Prior to sample analyses, the
analytical methods were validated for detection of the FBR anthocyanins in human saliva,
plasma and tissues by using internal standards “spiked” with human saliva, plasma and
tissue, respectively.
Determination of the Effect of Human Saliva on Cyanidin 3-Rutinoside
Results from our time course studies revealed one donor (TC001) whose saliva samples
contained cyanidin 3-glucoside as the predominant FBR anthocyanin. These data suggested
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that the predominant FBR anthocyanin (cyanidin 3-rutinoside, a disaccharide containing
rhamnose+glucose) was undergoing decomposition to the monosaccharide cyanidin 3-
glucoside (glucose only) in the oral cavity. Studies were therefore conducted on saliva
collected from five donors, one of whom (SAL001) was the same donor with the unique
time course saliva anthocyanin distribution (TC001) (Table IV). Four milliliters of saliva
were collected from all donors, with 1 ml to serve as the donors’ baseline. Rutinoside (50
μM final concentration) was added to the remaining 3 ml, and the saliva was aliquoted into
samples designated for the 1, 2, and 4 h time points. To account for rutinoside degradation in
the absence of human salivary enzymes, rutinoside (50 μM final concentration) was placed
in an artificial saliva (pH 7.4, reagents listed in final concentrations) which consisted of:
sodium carboxymethylcellulose (0.5%), sorbitol (165 mM), NaCl (14 mM), KCl (16 mM),
calcium chloride dehydrate (1.0 mM), MgCl2 (0.63 mM), and Trizma hydrochloride (2.0
mM). All saliva samples were incubated (37°C, 5% CO2) on a gently rocking platform. At
the designated time points, saliva samples were promptly acidified (1% formic acid, final
concentration) and frozen at −80°C until LC/MS/MS analyses.
Statistical Analyses
Comparisons of anthocyanin distribution in the saliva, tissue and plasma samples were
conducted using a two tailed Mann Whitney U test. Intra-donor comparisons of anthocyanin
levels contained in the donor-matched saliva and tissue samples were evaluated using a one-
way Chi square analysis. Findings with p values <0.05 were considered to be significant.
RESULTS
Levels of Anthocyanins in the 10% FBR Gel
Anthocyanin levels in the berry gel used in the tissue–saliva–plasma analyses were (ng/mg,
mean ± SD, n=9): cyanidin 3-rutinoside (2,749.7±359.97), cyanidin 3-xylosylrutinoside
(1,567.7±108.70), cyanidin 3-sambubioside (603.5±46.89) and cyanidin 3-glucoside
(536.1±54.43). These values, which compare favorably to the relative anthocyanin
proportions found in black raspberries (24), verified that the natural black raspberry
anthocyanin distribution was not perturbed during gel formulation. Similarly, the FBR
anthocyanin levels in the gel used for the time course and sublingual gel application studies
[(nanograms per milligram mean + SD, n=3): cyanidin 3-rutinoside (2,208.4±17.91),
cyanidin 3-xylosylrutinoside (1,418.1±53.58), cyanidin 3-sambubioside (339.4±20.91) and
cyanidin 3-glucoside (347.3±8.05)] also reflected the naturally occurring FBR anthocyanin
distribution.
The retromolar pad application site, single time point analyses of saliva, plasma and tissue
samples demonstrate site-specific anthocyanin localization and appreciable interdonor
variations. The respective levels of the four FBR anthocyanins contained in the saliva
samples paralleled the anthocyanin distribution found in FBR and the tested gel in the
majority of donors. Donor saliva volumes (milliliter) were: mean±SEM=2.37±0.57,
min=0.50, max=9.62, fold difference=19.24. The total black raspberry anthocyanins
(micrograms) retained in human saliva were: cyanidin 3-glucoside: mean
±SEM=31.82±7.92, min=1.66, max=152.52, fold difference=91.89; cyanidin 3-
sambubioside: mean=40.22±9.85, min=1.47, max=176.63, fold difference=120.16; cyanidin
3-rutinoside: mean=218.82±49.42, min=16.49, max=914.73, fold difference=55.47;
cyanidin 3-xylosylrutinoside mean=126.56±31.07, min=7.17, max=569.30, fold
difference=79.40. The mean percent uptake±SEM of the respective anthocyanins in saliva
were: cyanidin 3-glucoside=14.44±3.76; cyanidin 3-sambubioside=13.33±3.27; cyanidin 3-
rutinoside=18.26±4.09; cyanidin 3-xylosylrutinoside=16.15±3.96, for an overall average of
15% anthocyanin uptake in saliva.
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Analyses of tissue samples for anthocyanin content also revealed extensive interdonor
variations (Table V). Cyanidin 3-rutinoside and cyanidin 3-xylosylrutinoside were the
highest and second highest anthocyanins detected in the tissue samples; data which conform
to the relative anthocyanin distribution in FBR. Despite the fact that cyanidin 3-glucoside is
present at lower concentrations in FBR that cyanidin 3-sambubioside, more donors’ tissues
(n=14) contained cyanidin 3-glucoside and at higher mean levels than cyanidin 3-
sambubioside (n=5) (Table V). Three donors’ tissues did not contain detectable levels of any
FBR anthocyanins, while five tissue samples contained detectable levels of all four FBR
anthocyanins (Table V). The majority of donors’ tissues (n=9) contained three anthocyanins
i.e. cyanidin 3-rutinoside, cyanidin 3-xylosylrutinoside and cyanidin 3-glucoside. Results
from the anthocyanin stability tissue processing studies showed an approximate 55% and
87% cyanidin 3-rutinoside recovery in the samples that contained 500 ng/ml and 32 μg/ml,
respectively.
Donors that contained detectable levels of all 4 FBR in their tissue (nos. 008, 010, 012, 013
and 021) also showed relatively high anthocyanin levels in their saliva. In contrast, donors
with tissues that showed no anthocyanin uptake (005, 009, 018) contained low-average
salivary anthocyanin levels. Similar to the saliva samples, appreciable interdonor differences
were noted in the tissue anthocyanin levels. The overall average of anthocyanin uptake into
treated tissues was 0.0217% following a single topical FBR gel application (Table V).
Levels of FBR anthocyanins were non-detectable in the single time point, retromolar pad
application plasma samples. These data confirm that 5 min after gel application to
keratinized intact oral mucosa, the plasma levels of the respective anthocyanins were below
0.2 ng/ml.
Although many of the donors’ daily and intraoperative medications have reported effects
(either increase or decrease) on saliva production (Table I), no statistically significant
correlations between medications received and anthocyanin levels were identified.
Compartmentalization of FBR Anthocyanins Within Saliva and Tissue Samples
Levels of all four FBR anthocyanins were significantly higher in saliva relative to plasma
(p<0.001). Likewise, levels of cyanidin 3-rutinoside (p<0.002), cyanidin 3-xylosylrutinoside
(p<0.002) and cyanidin 3-glucoside (p<0.05) were significantly greater in tissue relative to
plasma. The majority of the donors’ tissues did not contain detectable levels of cyanidin 3-
sambubioside, resulting in extensive overlap between the tissue and plasma samples.
Consequently, these data were not significant. In addition, the mean uptake of FBR
anthocyanins into saliva was approximately 368 fold higher relative to levels achieved in
tissues.
Due to their reported effects on saliva, both the daily and intraoperative medications could
affect local gel clearance. Therefore, intra-donor comparisons of detectable anthocyanin
levels in donor-matched saliva and tissue were also conducted. In every comparison, FBR
anthocyanins were distributed at higher levels in saliva relative to donor-matched tissues
(p<0.001 for all four FBR anthocyanins).
Collectively, the single time point saliva, plasma and tissue data demonstrate a
saliva>tissue>plasma distribution for FBR anthocyanins following gel application to intact,
keratinized oral tissue.
Effect of Oral Mucosal Tissue Site on Anthocyanin Distribution
Results from the single time point (5 min post gel application) sublingual gel application
studies reveal that application site impacts anthocyanin distribution. Mean percent retention
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±SEM of the respective black raspberry anthocyanins retained in saliva were: cyanidin 3-
glucoside=3.531±2.05; cyanidin 3-sambubioside=7.361±4.31; cyanidin 3-
rutinoside=6.721±4.41, cyanidin 3-xylosylrutinoside=5.331±3.03, for an overall mean of
5.741±0.85 anthocyanin retention in saliva. These data show that relative to the retromolar
pad application site, a lower percent of gel was present in saliva following sublingual
application. Further, none of the plasma samples from this experimental group contained
any detectable levels of FBR anthocyanins.
Results from the time course, retromolar pad application studies (Table VI) reveal
persistence of FBR anthocyanins in saliva over time. Anthocyanin levels were detectable in
all donors’ saliva at the 1 h time point. Further, two of the five donors retained detectable
FBR anthocyanins in their saliva through the 4 h post application time point. One of these
donors (TC002) demonstrated detectable levels of all four FBR anthocyanins, in the
“standard” FBR anthocyanin distribution i.e. rutinoside highest, glucoside lowest, at all time
points. Donor TC001’s saliva profile was unique in that glucoside rather than rutinoside,
represented the predominant anthocyanin at all time points. This distribution, which
suggested the potential for a unique cyanindin 3-rutinoside decomposition profile, was the
basis for the cyanidin 3-rutinoside saliva incubation studies.
Time course plasma analyses revealed the presence of FBR anthocyanins in one (TC001) of
the five donors. This donor’s plasma contained levels (nanograms per milliliter) of cyanidin
3-rutinoside of 0.24 (1 h) and 0.28 (4 h) and of cyanidin 3-xylosylrutinoside 0.24 (4 h).
None of the other time course donors’ plasma samples contained any detectable levels of
FBR anthocyanins.
Conditions Present in Human Saliva Appear to Promote Decomposition and/or Metabolism
of Cyanidin 3-Rutinoside
The cyanidin 3-rutinoside standard contains trace amounts of cyanidin 3-glucoside. Relative
to the artificial saliva samples, all of the donors’ saliva samples contained lower cyanidin 3-
glucoside levels at all time points (Table VII). Two donors (001 and 002) demonstrated low
levels of cyanidin 3-rutinoside in their baseline control saliva samples. These same donors’
samples (001, 002) showed a progressive decrease in cyanidin 3-glucoside levels over the
experimental time course. In contrast, a more erratic distribution (initial decrease, then an
increase) was apparent the other donors’ samples (Table VII). Appreciable interdonor
variations were apparent with regard to cyanidin 3-rutinoside retention (Table VII). While
some cyanidin 3-rutinoside decomposition occurred in the artificial saliva samples (recovery
rate of ~57%), the levels of cyanidin 3-glucoside and cyanidin 3-rutinoside remained
constant over time. These data show that the artificial saliva samples did not demonstrate a
comparable decomposition and/or metabolic conversion profile as that observed in the
human saliva samples.
DISCUSSION
Results from our oral epithelial dysplasia berry gel trial demonstrated appreciable
interpatient variations with regard to the extent of chemopreventive efficacy (21,22). We
speculate that these disparities reflect, at least in part, patient-related differences in FBR
absorption and target tissue uptake. Those clinical trial findings were the basis for this
current study which assessed the distribution of the 10% FBR gel in oral tissues, saliva and
plasma.
Anthocyanins are the predominant black raspberry phenolic compounds (24). Previous
investigations from our labs have demonstrated high chemopreventive impact in
anthocyanin-enriched FBR fractions, including modulation of gene expression and
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suppression of pro-inflammatory enzymes (15,24,25). Notably, cyanidin glycosides were
identified as the FBR components responsible for inhibition of benzo[a]pyrene-7,8-
diol-9,10-epoxide mediated transcription factor activation (25). Consequently, FBR
anthocyanins were selected as the monitored compounds in this study. It is generally
accepted that anthocyanins have limited absorption from the gastrointestinal tract (27).
Results from this current study, which show target tissue anthocyanin uptake and
sustainability at the target site, imply that a topically applied bioadhesive gel is a plausible
strategy to counteract poor systemic anthocyanin absorption.
Our results demonstrated large interdonor variations in anthocyanin uptake in saliva and
tissue. These data are consistent with other human studies that evaluated tissue
pharmacokinetic and distribution parameters using local intraoral delivery methods (28-31).
These large interdonor variations likely reflect the extensive heterogeneity among humans
regarding compound retention and uptake-modifying parameters such as rate of saliva
secretion and clearance, extent of tissue keratinization and local tissue anthocyanin
metabolism or decomposition.
Unique aspects of this current study, i.e. delivery formulation, compounds evaluated, short
duration for the pharmacokinetic analyses, and conduction of post gel application tissue
biopsies make direct comparisons to previous investigations difficult. Regardless, our
average gel-mediated anthocyanin delivery values obtained in saliva [(7.99%, 5 min post
application, retromolar pad) and (0.045%, highest FBR anthocyanin, 1 h post application,
retromolar pad)] compare favorably to results obtained in previous investigations which
assessed local intraoral agent delivery. Investigations by Cardot et al. determined saliva and
plasma levels of miconazole to assess local delivery efficacy of two dosing formulations of
bioadhesive tablets relative to a topically applied gel (29). The mean saliva levels obtained
by topical gel application in the Cardot study were 0.74% (29). While the Cardot et al.
compound uptake was assessed at 30 min post application, our data were collected at 5 min
and 1 h time points. Studies by Sobeck et al., which investigated levels of vitamin A
derivatives in buccal keratinocytes following use of a retinyl palmitate containing
toothpaste, determined approximately 0.1% of the applied dose (approximately five fold
greater than our tissue uptake) was internalized by oral keratinocytes (28). Differences
between the Sobeck and this current study include: formulation (toothpaste versus
bioadhesive gel), dosing duration (56 days versus single application), tissues evaluated
(superficial differentiated keratinocytes versus intact oral mucosa) and solubility of the
targeted compound [vitamin A (fat soluble) and anthocyanins, (water soluble)] (28).
Three donors’ tissues did not contain any detectable levels of FBR anthocyanins. While all
of these individuals’ saliva contained all four FBR anthocyanins, their salivary anthocyanin
levels were low to average. Also, one of these donors (STP005) had the second highest
saliva volume, which would have an overall diluting effect and facilitate gel clearance. With
regard to compound uptake and penetration, oral mucosa is intermediate between gastric
mucosa (more permeable) and skin (less permeable) (32). Modulating factors for oral tissue
compound uptake include degree of keratinization, extent and chemical nature of inter-
epithelial cell lipid packaging, tissue biofilm and associated bacteria (surfactant and/or
anthocyanin metabolism properties), salivary flow and clearance and relative number of
tight junctions (33). It is also necessary to consider the contributions of the Na+-dependent
glucose transporter (SGLT1) as well as the multidrug resistance protein 2 (MRP2) when
assessing intracellular anthocyanin levels as these systems have been shown to affect
anthocyanin cellular uptake and export, respectively (27,34-36). The absence of
anthocyanins in these three donors’ tissues could reflect the effects of one or more of the
variables cited above. Finally, the results from the tissue processing-anthocyanin studies,
which showed lower anthocyanin recovery from tissues with the lower, analogous to tissue
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sample concentrations, suggest that our data underestimate tissue anthocyanin levels
following gel application.
In this current study, plasma levels of anthocyanins were only detectable in one time course
donor (TC001). In contrast, Lawrence et al.’s study demonstrated that even the lowest gel
dose (0.5% ketoprofen, 5 mg b.i.d. for 14.5 days) resulted in plasma ketoprofen levels (30).
Obvious differences between the Lawrence and this current study include application site:
(periodontally inflamed tissues which have increased vascularity and may have
microulcerations relative to intact, keratinized oral mucosa) and dosing frequency (multiple
doses over time versus single application) (30). Unlike our previous findings, which
demonstrated plasma anthocyanin levels 5 min after gel application (20), this current study
did not detect any plasma anthocyanin levels following gel application to the same site i.e.
sublingual. These data imply that a more basic pH (prototype gel pH 6.5, clinical trial and
this study gel pH 3.5) enhances gel penetrative capacities, potentially by facilitating
paracellular anthocyanin transport. Our results show a relatively rapid time course for FBR
gel penetration in human oral mucosa i.e., 5 min following sublingual administration of the
prototype pH 6.5 gel (20) and 1 h following application to keratinized tissues (TC001). In
contrast, previous studies that employed an in vitro model of oral epithelium showed a much
slower penetration of the tested compounds (37). These disparate results likely reflect
experimental differences that include tissues evaluated (intact oral mucosa relative to an in
vitro model), method of administration (topical application by rubbing the gel in situ versus
addition into media), presence or absence of circulation and salivary flow, and presence or
absence of a mucoadhesive vehicle.
The time course saliva results showed cyanidin 3-glucoside as the predominant anthocyanin
in one donor. Although the time course saliva incubation studies demonstrated variable
cyanidin 3-glucoside levels over time in three donors’ samples, these data are not
convincing evidence to support conversion of cyanidin 3-rutinoside to cyanidin 3-glucoside.
These findings, in conjunction with the results that showed a greater number of tissues
retained cyanidin 3-glucoside relative to cyanidin 3-sambubioside (which is contained at
higher levels in FBR) suggest a higher persistence of the monosaccharide cyanidin 3-
glucoside relative to the other three FBR anthocyanins in some persons.
The extent of cyanidin 3-rutinoside recovery was appreciably lower in human saliva samples
relative to artificial saliva. These data are consistent with the presence of glycosidases in
human saliva that are capable of hydrolyzing flavonoid glycosides to the more
chemopreventive-effective aglycones (38). These previous studies also demonstrated a large
interdonor variability in glycosidase activities (38). As the cyanidins are superior
antioxidants, interpatient differences in glycosidase activities may be at least partially
responsible for our observed variations in chemopreventive efficacy (21,22). In addition to
glycosidases, other anthocyanin metabolizing enzymes include catechol-O-
methyltransferase, uridine diphosphate (UDP)-glucuronosyl transferase and UDP-glc-
dehydrogenase (27,34). Previous studies from our labs demonstrated that methylation is the
predominant anthocyanin metabolizing pathway following oral FBR administration to
humans (39). Anthocyanins can also undergo decomposition, which entails formation of the
corresponding phenolic acid from the B-ring of the anthocyanin skeleton (40). While the
more complex di and trisaccharide anthocyanins are considered less degradation-susceptible
than their monosaccharide counterparts, our data suggest that conditions present in human
saliva promote decomposition and/or metabolism of the disaccharide cyanidin 3-rutinoside.
While previous oral cavity chemoprevention trials monitored a wide variety of therapeutic
outcomes including clinical and microscopic appearances, and molecular parameters such as
loss of heterozygosity indices or DNA ploidy (8-14), none of these studies assessed
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pharmacokinetic parameters or local tissue distribution. The key findings of this current
study i.e. marked donor-specific variations in agent uptake, sustainability of therapeutic
compounds at the target site, demonstration of target tissue uptake and data consistent with
anthocyanin decomposition and/or metabolism in the oral environment have implications
that could affect clinical efficacy. We anticipate that these data, in conjunction with
complementary metabolism studies, will provide beneficial insights that will advance oral
cavity chemoprevention.
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Table I
Demographic Data of Participants for the Saliva, Tissue and Plasma Analyses
Donor Age Gender Daily medications and effect(s) on saliva Intraoperative medications and effect(s) on saliva
STP002 29 F None None
STP004 25 F Loratadine (decrease) Nitrous oxide (none)
Albuterol (decrease)
STP005 25 F Sertraline (decrease) None
Propanolol (decrease)
STP006 18 F None None
STP007 20 M None 50 μg fentanyl (decrease)
2 mg midazolam (increase)
STP008 30 F None None (none)
STP009 25 M None 2 mg midazolam (increase)
25 μg fentanyl (decrease)
5 mg diazepam (increase)
STP010 22 F None 10 mg diazepam (increase)
25 mg Demerol (decrease)
STP011 20 M Clopidrogel, aspirin, nabumetone, somatropin,
methylprednisolone
1 mg midazolam (increase)
25 μg fentanyl (decrease)
STP012 25 F Lamotrigine (decrease) 15 mg diazepam (increase)
Medroxyprogesterone 50 mg Demerol (decrease)
STP013 22 M None 15 mg diazepam (increase)
50 mg Demerol (decrease)
STP014 25 F None 15 mg diazepam (increase)
50 mg Demerol (decrease)
STP015 31 M None 2 mg midazolam (increase)
50 μg fentanyl (decrease)
5 mg diazepam (increase)
STP016 31 M None 50 μg fentanyl (decrease)
1 mg midazolam (increase)
STP017 26 F Birth control pills None
STP018 23 M None 25 μg fentanyl (decrease)
2 mg midazolam (increase)
STP019 25 F None None
STP020 23 M Vitamins 2 mg midazolam (increase)
50 μg fentanyl (decrease)
5 mg diazepam (increase)
STP021 25 F Vitamins 10 mg diazepam (increase)
50 mg Demerol (decrease)
STP022 34 F None 5 mg diazepam (increase)
50 mg Demerol (decrease)
STP023 22 F None Nitrous oxide (None)
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AHFS Drug Information® 2008 (http://www.ahfsdruginformation.com) was used to determine the effects of medications on saliva
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Table II
Demographic Data of Participants for the Time Course Saliva and Plasma Analyses
Donor Age Gender Prescription medications
TC001 54 F Montelukast, Azelastine
TC002 61 M Atenolol, Atorvastatin, Clopidogrel, Acetylsalicylic acid, Ezetimibe, Rabeprazole, Fosinopril
TC003 27 M None
TC004 26 M None
TC005 29 M Finasteride
AHFS Drug Information® 2008 (http://www.ahfsdruginformation.com) was used to determine the effects of medications on saliva
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Table III
Demographic Data of Participants for the Sublingual, Single Time Point Saliva and Plasma Analyses
Donor Age Gender Prescription Medications
ST001 22 M Fexofenadine
ST002 20 M None
ST003 30 M None
ST004 39 F Estrogen patch, vitamin B12
ST005 28 M None
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Table IV
Demographic Data of Participants for the Rutinoside-Saliva Time Course Incubation Studies
Donor Age Gender Prescription medications
SL 001 54 F Montelukast, Azelastine. Note: same donor as TC001
SL 002 46 F None
SL 003 32 M None
SL 004 22 M Allegra. Note: same donor as ST001
SL 005 20 M None. Note: same donor as ST002
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Table V
Black Raspberry Anthocyanin Levels in Oral Mucosa (Nanograms per Milligram Protein) and Percent
Anthocyanin Uptake
Sample ID Cyanidin 3-glucoside Cyanidin 3-sambubioside Cyanidin 3-rutinoside Cyanidin 3-xylosylrutinoside
Tissue 002 ND (0%) ND (0%) 48.83 (0.0035%) 39.17 (0.0050%)
Tissue 004 24.63 (0.0092%) ND (0%) 62.31 (0.0045%) 36.30 (0.0046%)
Tissue 005 ND (0%) ND (0%) ND (0%) ND (0%)
Tissue 006 181.09 (0.0667%) ND (0%) 365.45 (0.0265%) 249.82 (0.0320%)
Tissue 007 43.21 (0.0161%) ND (0%) 145.71 (0.0106%) 76.96 (0.0098%)
Tissue 008 48.39 (0.180%) 66.26 (0.0220%) 121.70 (0.0088%) 75.39 (0.0096%)
Tissue 009 ND (0%) ND (0%) ND (0%) ND (0%)
Tissue 010 38.23 (0.0143%) 35.45 (0.0118%) 167.44 (0.0121%) 88.90 (0.0113%)
Tissue 011 46.00 (0.0172%) ND (0%) 126.63 (0.0092%) 79.50 (0.0101%)
Tissue 012 30.76 (0.0115%) 26.27 (0.0087%) 119.04 (0.0086%) 62.52 (0.0080%)
Tissue 013 28.64 (0.0107%) 20.42 (0.0068%) 177.01 (0.0128%) 55.95 (0.0071%)
Tissue 014 3.45 (0.0013%) ND (0%) 5.92 (0.0004%) 2.66 (0.003%)
Tissue 015 ND (0%) ND (0%) 253.75 (0.0184%) 152.19 (0.0194%)
Tissue 016 71.28 (0.0266%) ND (0%) 161.28 (0.0117%) 118.80 (0.0152%)
Tissue 017 ND (0%) ND (0%) 876.00 ((0.0635%) ND (0%)
Tissue 018 ND (0%) ND (0%) ND (0%) ND (0%)
Tissue 019 417.50 (0.1557%) ND (0%) 936.25 (0.0679%) 671.25 (0.0856%)
Tissue 020 16.99 (0.0063%) ND (0%) 56.86 (0.0041%) 30.90 (0.0039%)
Tissue 021 325.78 (0.1215%) 270.16 (0.0895%) 1,393.44 (0.1012%) 703.44 (0.0897%)
Tissue 023 274.29 (0.1023%) ND (0%) 1,079.14 (0.0783%) 659.14 (0.0841%)
Mean (ng/mg all samples
±SEM)
77.51±26.64 20.93±13.32 304.84±90.15 155.14±50.86
Mean (ng/mg detectable
only±SEM)
110.73±35.73 83.71±47.19 358.64±427.40 193.93±246.91
MIN 3.45 20.42 5.92 2.66
MAX 417.50 270.16 1,393.44 703.44
Fold difference 121.11 13.23 235.34 264.66
Mean % anthocyanin
uptake + SEM
0.0289±0.010 0.0060±.0045 0.0221±.007 0.0298±.007
Mean % anthocyanin uptake for all 4 FBR anthocyanins=0.0217±0.0055
Limits of detection were 2 ng/ml for cyanidin 3-rutinoside, cyanidin 3-glucoside and cyanidin 3-xylosylrutinoside and 5 ng/ml for cyanidin 3-
sambubioside. (Anthocyanins (nanograms) delivered per 0.5 g gel: glucoside = 268,100; sambubioside = 301,700; rutinoside = 1,378,800;
xylosylrutinoside = 783,900.) Gel application site = retromolar pad
ND not detectable
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Table VI
Time Course (TC) Levels of Salivary Anthocyanins
Sample ID Cyanindin 3-glucoside Cyanidin 3-sambubioside Cyanindin 3-rutinoside Cyanidin 3-xylosylrutinoside
TC001 1 h 65.63 (0.04%) 9.06 (0.005%) 53.77 (0.005%) 25.57 (0.004%)
TC001 2 h 30.59 (0.02%) ND 0% 5.63 (0.0005%) ND 0%
TC001 4 h 34.40 (0.02%) ND 0% 5.38 (0.0005%) ND 0%
TC002 1 h 112.31 (0.065%) 230.97 (0.136%) 1,895.19 (0.172%) 954.74 (0.135%)
TC002 2 h 21.29 (0.012%) 49.76 (0.029%) 401.67 (0.036%) 225.97 (0.032%)
TC002 4 h 2.97 (0.002%) 15.49 (0.009%) 68.16 (0.006%) 60.13 (0.008%)
TC003 1 h ND (0%) 19.60 (0.012%) 91.74 (0.008%) 35.30 (0.005%)
TC003 2 h ND (0%) ND (0%) 14.31 (0.001%) 3.30 (0.0005%)
TC003 4 h ND (0%) ND (0%) 4.30 (0.0004%) ND (0%)
TC004 1 h ND (0%) ND (0%) 8.40 (0.0008%) ND (0%)
TC004 2 h ND (0%) ND (0%) 7.64 (0.0006%) ND (0%)
TC004 4 h ND (0%) ND (0%) ND (0%) ND (0%)
TC005 1 h ND (0%) ND (0%) 13.79 (0.0012%) 4.56 (0.0006%)
TC005 2 h ND (0%) ND (0%) 10.32 (0.0010%) ND (0%)
TC005 4 h ND (0%) ND (0%) ND (0%) ND (0%)
(Anthocyanins (nanograms) delivered per 0.5 g gel: glucoside = 173,700; sambubioside = 169,700; rutinoside = 1,104,200; xylosylrutinoside =
709,400.) Gel application sites: single time point (sublingual), time course (retromolar pad)
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Table VII
Effect of Incubation with Human Saliva on Cyanidin 3-Rutinoside (Cyn 3-rut) and Cyanidin 3-Glucoside (Cyn
3-glu) Levels
Sample Cyn 3-glu (ng/ml) Cyn 3-rut (ng/ml) Cyn 3-rut (μM) % recovery cyn 3-
SL 001 con ND 24.35 0.04 NA
SL 001 1 h 182.15 11,222.11 18.86 37.72
SL 001 2 h 78.95 11,087.80 18.63 37.27
SL 001 4 h 28.55 10,791.50 18.14 36.27
SL002 con ND 32.14 0.05 NA
SL 002 1 h 50.17 2,782.75 4.68 9.35
SL 002 2 h 11.88 1,158.87 1.95 3.90
SL 002 4 h ND 337.14 0.57 1.13
SL 003 con ND ND ND NA
SL 003 1 h 147.84 6,566.43 11.04 22.07
SL 003 2 h 37.95 2,361.69 3.97 7.94
SL 003 4 h 78.22 8,611.56 14.47 28.95
SL 004 con ND ND ND NA
SL 004 1 h 42.87 2,193.05 3.69 7.37
SL 004 2 h ND 635.56 1.07 2.14
SL 004 4 h 167.74 8,750.34 14.71 29.41
SL 005 con ND ND ND NA
SL 005 1 h 12.85 1,244.11 2.09 4.18
SL 005 2 h 18.10 1,517.49 2.55 5.10
SL 005 4 h ND 1,056.11 1.77 3.55
AS00C con ND ND ND NA
AS001 1 h 528.47 16,445.69 27.64 55.28
AS001 2 h 511.27 17,414.73 29.27 58.54
AS001 4 h 515.63 17,147.27 28.82 57.64
(Baseline levels prior to addition of anthocyanin standard)
AS artificial saliva, ND not detected, NA not applicable, con control samples
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